Paper19680293
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Gazdar AF. Oncogene, 2009. Cited by 797 papers, by iCite.
Cite this record
ConductScience Library. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Papers, record 19680293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19680293
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| ErbB Receptors | Major topic |
| Lung Neoplasms | Major topic |
| Point Mutation | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Erlotinib Hydrochloride | |
| Gefitinib | |
| Gene Amplification | |
| Humans | |
| Protein Structure, Tertiary | |
| Proto-Oncogene Proteins | |
| Proto-Oncogene Proteins c-met | |
| Proto-Oncogene Proteins p21(ras) | |
| Quinazolines | |
| Receptors, Growth Factor | |
| Sequence Deletion | |
| Treatment Outcome | |
| ras Proteins |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P50 CA070907 | NCI NIH HHS | United States | P50CA070907 | PubMed and NIH |
| P50CA70907 | NCI NIH HHS | United States | P50CA070907 | PubMed and NIH |
Source NIH RePORTER
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14570950 | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. | JAMA | 2003 | https://conductscience.org/library/papers/14570950 | PubMed |
| 2 | 16187797 | Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. | PLoS Med | 2005 | https://conductscience.org/library/papers/16187797 | PubMed |
| 3 | 16777603 | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. | Cell | 2006 | https://conductscience.org/library/papers/16777603 | PubMed |
| 4 | 19276259 | Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19276259 | PubMed |
| 5 | 17671147 | HKI-272 in non small cell lung cancer. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17671147 | PubMed |
| 6 | 15738541 | Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15738541 | PubMed |
| 7 | 15851406 | Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. | Ann Oncol | 2005 | https://conductscience.org/library/papers/15851406 | PubMed |
| 8 | 18375904 | Structure and clinical relevance of the epidermal growth factor receptor in human cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18375904 | PubMed |
| 9 | 15604253 | Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. | Cancer Res | 2004 | https://conductscience.org/library/papers/15604253 | PubMed |
| 10 | 18355544 | Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. | Ann Thorac Surg | 2008 | https://conductscience.org/library/papers/18355544 | PubMed |
| 11 | 16705038 | Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. | Genes Dev | 2006 | https://conductscience.org/library/papers/16705038 | PubMed |
| 12 | 16014882 | Erlotinib in previously treated non-small-cell lung cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16014882 | PubMed |
| 13 | 18227510 | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18227510 | PubMed |
| 14 | 15710947 | Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15710947 | PubMed |
| 15 | 16467097 | Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16467097 | PubMed |
| 16 | 16912195 | Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. | Cancer Res | 2006 | https://conductscience.org/library/papers/16912195 | PubMed |
| 17 | 16818686 | Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16818686 | PubMed |
| 18 | 16204070 | Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. | Cancer Res | 2005 | https://conductscience.org/library/papers/16204070 | PubMed |
| 19 | 16043828 | Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16043828 | PubMed |
| 20 | 18509184 | Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18509184 | PubMed |
Cited by495
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 797 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42959345 | Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42959345 | PubMed |
| 42794834 | Time-Resolved Network Entropy Analysis Identifies a CTNND1-VAV3 Subnetwork in Gefitinib-Resistant NSCLC. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794834 | PubMed |
| 42723470 | Discovery of Potent EGFR Inhibitors for Del19 and L858R/T790M Mutants Through Structure-Based Virtual Screening and Biological Evaluation. | Chem Biol Drug Des | 2026 | https://conductscience.org/library/papers/42723470 | PubMed |
| 42653127 | From Descriptor Learning to Binding Stability: An Explainable Machine Learning Pipeline for EGFR Double-Mutant Inhibitor Discovery. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653127 | PubMed |
| 42361448 | Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma. | ESMO Open | 2026 | https://conductscience.org/library/papers/42361448 | PubMed |
| 42291370 | Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42291370 | PubMed |
| 42249090 | Integrative structural and dynamics studies of epidermal growth factor receptor (EGFR). | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42249090 | PubMed |
| 42170254 | The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42170254 | PubMed |
| 42154197 | EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions. | Drugs | 2026 | https://conductscience.org/library/papers/42154197 | PubMed |
| 42142369 | Gender Differences in EGFR-TKI-Related Adverse Events: A Pharmacovigilance Study Based on the FAERS Database. | Cancer Control | 2026 | https://conductscience.org/library/papers/42142369 | PubMed |
| 42101621 | The critical role of accurate neoplastic cell percentage (NCP) assessment: investigating targeted training strategies for pulmonary biopsy and cytology specimens. | Virchows Arch | 2026 | https://conductscience.org/library/papers/42101621 | PubMed |
| 42006277 | Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study). | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/42006277 | PubMed |
| 41822315 | Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates. | World J Oncol | 2026 | https://conductscience.org/library/papers/41822315 | PubMed |
| 41799114 | EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances. | ACS Omega | 2026 | https://conductscience.org/library/papers/41799114 | PubMed |
| 41743381 | The relationship between genetic mutations and organ metastasis in non-small cell lung cancer. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/41743381 | PubMed |
| 41710724 | Frequency of the L858R Mutation in Exon 21 of the Epidermal Growth Factor Receptor in Patients with Non-Small Cell Lung Cancer. | Iran J Pathol | 2026 | https://conductscience.org/library/papers/41710724 | PubMed |
| 41710084 | Metastatic breast cancer in primary lung cancer with compound EGFR mutations: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/41710084 | PubMed |
| 41670652 | Beyond the membrane: rethinking EGFR signaling in physiology and cancer. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/41670652 | PubMed |
| 41592227 | IsoPS-DIA: Dual Functionality of Absolute Targeted Quantification and Global Proteome Profiling. | Anal Chem | 2026 | https://conductscience.org/library/papers/41592227 | PubMed |
| 41590374 | Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? | Curr Oncol | 2026 | https://conductscience.org/library/papers/41590374 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19680293
GET https://conductscience.org/api/papers/v1/19680293/references?page=2